To discover novel genetic risk factors underlying amyotrophic lateral sclerosis (ALS), we aggregated exomes from 3,864 cases and 7,839 ancestry matched controls. We observed a significant excess of ultra-rare and rare protein-truncating variants (PTV) among ALS cases, which was primarily concentrated in constrained genes; however, a significant enrichment in PTVs does persist in the remaining exome. Through gene level analyses, known ALS genes, SOD1, NEK1, and FUS, were the most strongly associated with disease status. We also observed suggestive statistical evidence for multiple novel genes including DNAJC7, which is a highly constrained gene and a member of the heat shock protein family (HSP40). HSP40 proteins, along with HSP70 proteins, facilitate protein homeostasis, such as folding of newly synthesized polypeptides, and clearance of degraded proteins. When these processes are not regulated, misfolding and accumulation of degraded proteins can occur leading to aberrant protein aggregation, one of the pathological hallmarks of neurodegeneration.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disease characterized primarily by degeneration of motor neurons leading to progressive weakness of limb, bulbar, and respiratory muscles Strong et al., 2017) . Genetic variation is an important risk factor for ALS. Given that 5-10% of patients report a positive family history (AlChalabi et al., 2017) and ~10% of sporadic patients carry known familial ALS gene mutations, the distinction between familial and sporadic disease is increasingly blurred (Al-Chalabi, 2017) .
Until recently, ALS gene discoveries were made through large multigenerational pedigrees in which the gene and the causal variant segregated in an autosomal dominant inheritance pattern with very few cases of autosomal recessive inheritance reported. Collecting sporadic case samples has been valuable for gene discovery in more common disorders such as schizophrenia (Singh et al., 2016) , inflammatory bowel disease (Mohanan et al., 2018) , and type 2 diabetes (Manning et al., 2017) , and can have profound effects on the success of targeted therapeutic approaches Hamburg and Collins, 2010; Nelson et al., 2015) . The most recent ALS genetic discoveries using large massively parallel sequencing data yielded several gene discoveries, TBK1, TUBA4A, ANXA11 and NEK1 and KIF5A (Cirulli et al., 2015; Kenna et al., 2016; Nicolas et al., 2018; Smith et al., 2014; Smith et al., 2017) ; in addition to other risk loci in C21orf2, MOBP, and SCFD1 (van Rheenen et al., 2016) .
Herein, we have assembled the largest ALS exome case-control study to date, consisting of 11,703 individuals (3,864 cases and 7,839 controls). We complemented our analysis by leveraging allele frequencies from large external exome sequencing databases in DiscovEHR (>50,000 samples; cite DiscovEHR) and a subset of ExAC (>45,000 samples) (Lek et al., 2016) .
In our analysis, we observed an excess of rare protein truncating variants (PTV) in ALS cases, which primarily resided in constrained genes. There was no enrichment of rare PTVs in genes known to confer risk to ALS; genes associated with clinically overlapping diseases; or genes in which their expression is specific to the brain.
Furthermore, through gene burden testing, we confirmed the known association of SOD1, NEK1, and FUS, while also observing PTVs in DNAJC7 in 4/3,864 cases and 0/28,910 controls.
DNAJC7 is a highly constrained gene, and encodes a DNAJ molecular chaperone, which facilitates protein maintenance and quality control, such as folding of newly synthesized polypeptides, and clearance of degraded proteins (Lackie et al., 2017) . Dysregulation of these processes can lead to aberrant protein aggregation, one of the pathological hallmarks of neurodegenerative diseases.
RESULTS

Patient demographics and dataset overview
We processed our initial dataset of 15,722 samples through a rigorous quality control pipeline using Hail, an open-source, scalable framework for exploring and analyzing genomic data https://hail.is/. We removed samples with poor sequencing quality, high levels of sequence contamination, closely related with one another, ambiguous sex status, or population outliers per PCA (Table S1 and Table S3 ). Our final data set consisted of 11,703 samples: 3,864 cases and 7,839 controls. Individuals were of European descent with 7,355 samples (62.8%) classified as males. Of 3,864 cases, 2,274 samples (58.9%) were classified as males; where 5,081 samples (64.8%) were classified as males in controls.
Excess of exome-wide rare protein truncating variants
Using multiple firth based logistic regression analyses incorporating sample sex, PC1-PC10, and the total exome count (summation of synonymous variants, benign missense variants, damaging missense variants, and PTVs), we observed a significant enrichment of singleton PTVs in ALS cases relative to controls (OR: 1.07; 95% CI: 1.04-1.10; P-value: 5.00x10 -7); ultra-rare singleton PTVs Figure S8 ).
In our analyses, we define PTVs as a frameshift variant, a splice acceptor variant, a splice donor variant, or a stop gained variant, which are due to insertions or deletions (indels), or single nucleotide variants (SNVs). We divided PTVs as either SNVs or indels given their differences in error rates (Lam et al., 2011; O'Rawe et al., 2013) and repeated the exome-wide analysis. The significant signal is present in both SNVs and indels: SNV singletons (OR: 1.05; 95% CI: 1.02- Figure S10 ).
Gene set testing: enrichment of rare variants in constrained genes
To determine whether we could concentrate the PTVs enrichment, we assessed multiple different gene sets. We evaluated (1) constrained genes under strong purifying selection (Lek et al., 2016; Samocha et al., 2014) ; (2) genes known to confer risk to ALS; (3) genes associated with clinically overlapping diseases; and (4) genes in which their expression is specific to the brain ("brain specific").
Among constrained genes we observed a significant enrichment of singleton PTVs (OR: Figure 2A , Figure S11 ). We obtained similar results using model 4 ( Figure S11 Figure 2B , Figure S12 ). This was also observed in model 4 ( Figure S12 ). In model 3, the significant enrichment in damaging missense variants in the rare variants category initially observed in constrained gene disappears: Figure   3A , Figure S13 ). As expected, these observations were also supported by model 4 and the original signal in damaging missense variants persists ( Figure S13 ). Importantly however, when including variants from TBK1, NEK1, KIF5A, C21orf2, MOBP, or SCFD1, the signals persist.
Although ALS is traditionally considered to be a disease of upper and lower motor neurons, more than 50% of ALS patients exhibit neuropsychological and cognitive deficits, with up to 30% of ALS patients meeting some diagnostic criteria for frontotemporal dementia, and some patients may also exhibit Parkinsonism or Parkinsonism-dementia (Aarsland et al., 2005; Farhan et al., 2017; Farhan et al., 2018; Hely et al., 2008; Strong et al., 2017; Swinnen and Robberecht, 2014) . We surveyed the literature and tabulated a comprehensive list of genes associated with other motor neuron diseases such as primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and spinal muscular atrophy. We also included genes associated with the following overlapping phenotypes: frontotemporal dementia, Parkinson's disease, Pick's disease, and Alzheimer's disease. We did not observe a significant enrichment of variants in any class of variation, suggesting that the initial observation of PTV enrichment is likely not driven by genes associated with similar phenotypes ( Figure 3B , Figure   S15 ).
Finally, while the genes implicated in the development of ALS are not predominantly or preferentially expressed in motor neurons, nor are they all brain specific except for a select few, we tested whether there is a signal in brain specific genes as ALS is a neurodegenerative disease with the predominant symptoms affecting the central nervous system. We extracted a list of genes with specific brain expression generated using GTEx and performed the same burden analysis across classes of variation (Ganna et al., 2016) . As expected, we did not observe any significant differences in PTVs or damaging missense variation in any allele frequency threshold ( Figure 3C , Figure S16 ). These observations suggest the PTV signal initially observed in the exome-wide scan is also not driven by genes with specific brain expression, further corroborating the non-brain specific expression profiles of known ALS genes in the literature.
Single gene burden analysis replicates previous ALS associations
To determine whether a single gene is enriched for variation in ALS cases (ALS-associated) or depleted in ALS cases (ALS-protective), we evaluated ultra-rare (AC=1, absent in DiscovEHR) and rare (MAF <0.001% in our dataset, DiscovEHR, and ExAC) PTVs and damaging missense variants. Within the ultra-rare variant category, no individual gene passed exome-wide significance. However, the top genes were known ALS genes: (1 Table 1 , Figure 4A ; Figure S17A . Similarly, within damaging missense variants, SOD1 (OR: 87.7; 95%
CI: 10.6-1448.3; P-value: 7.5x10 -11) was the only gene to pass exome-wide significance; the top 9 most significant genes are displayed in Table 2 , Figure 4B ; Figure S17B .
To replicate our findings, we included an additional 21,071 controls from ExAC that are of European descent (non-Finnish) and were not a part of any psychiatric or brain related studies, to eliminate any sample overlap. We performed the same burden analyses using 3,864 cases and 28,910 controls (7,839 controls within our dataset and 21,071 additional controls). In Tables 1 and 2, we display the most significant genes that were identified in the initial discovery and tabulate their OR and P-values for both the initial discovery cohort (3,864 cases and 7,839 controls) and the secondary analysis (3,864 cases and 28,910 controls). Within PTVs, NEK1 is still the only gene that exceeds exome-wide significance (OR: 6.5; 95% CI: 3.6-11.5; P-value:
3.03x10 -10) ( Figure 4A , Figure S18 ). Of the next 9 most significant genes in the initial analysis, the only signal that was strengthened was in FUS (OR: 97.4; 95% CI: 8.8-1729.5; P-value:
2.68x10 -6). Importantly, the signal in OPTN, a proposed ALS associated gene decreased (OR:
6.6; 95% CI: 2.0-27.8; P-value: 3.0x10 Figure 4D , Figure S18 ).
DISCUSSION
Herein, we have assembled the exomes of 3,864 ALS cases and 7,839 controls and observed an exome-wide enrichment of PTVs, which typically result in protein loss of function. The abundance of PTVs in ALS cases seems to be primarily driven by constrained genes, which are under strong purifying selection. When removing constrained genes, the initial exome-wide enrichment of PTVs remains; however, the effect sizes are much smaller, suggesting there are residual effects in other genes. Accordingly, we examined the effects of ALS associated genes by removing them from the exome-wide analysis and detected the same PTV enrichment initially observed. Importantly, a subset of cases was pre-screened for known pathogenic variants in a select number of known ALS genes and positive cases were eliminated prior to assembling the dataset, which will attenuate the estimates of effect size and significance for genes in this gene set.
Acknowledging the phenotypic variability of ALS, we also evaluated the effects of genes implicated in other motor neuron diseases such as primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and spinal muscular atrophy; as well as genes associated with the following overlapping phenotypes: frontotemporal dementia, Parkinson's disease, Pick's disease, and Alzheimer's disease. We did not observe a significant enrichment of variants in any class of variation, suggesting that the initial observation of excess PTVs do not reside in these genes. Lastly, the genes implicated in the development of ALS are not specifically expressed in motor neurons, nor are they brain specific, a perplexing observation given the specific degree of degeneration of upper and lower motor neurons. Nevertheless, we tested whether the signal in datasets, we observed 2 and 7 putative PTVs, respectively; however, the majority of the PTVs resided within poor quality or multiallelic sites. One caveat of using the full gnomAD dataset is that a subset of ALS exomes and other related neurodegenerative diseases have been deposited into this resource, which prevents us from delineating PTVs from ALS versus non-ALS exomes.
When considering gnomAD genomes only (15,496 samples), there is only 1 putative PTV in DNAJC7 due to a splice variant, which may be rescued by a neighboring nucleotide. According to the HPA RNA-seq normal tissues project (Fagerberg et al., 2014) and the Genotype-Tissue Expression (GTEx) project (Consortium, 2013) , DNAJC7 is ubiquitously expressed with elevated expression in the brain. DNAJC7 encodes a molecular chaperone, DnaJ heat shock protein family (HSP40) member C7, and like all DNAJ proteins, contains an approximately 70 amino acid J-domain, which is critical for binding to HSP70 proteins (Jiang et al., 2007) . There are approximately 50 DNAJ proteins, which are also classified as HSP40 proteins, that facilitate protein maintenance and quality control, such as folding of newly synthesized polypeptides, and clearance of degraded proteins (Kampinga and Craig, 2010; Lackie et al., 2017; Mayer and Bukau, 2005) . Specifically, DNAJs act as co-chaperones for HSP70 proteins by regulating
ATPase activity, aid in polypeptide binding, and prevention of premature polypeptide folding (Clerico et al., 2015; Mayer and Bukau, 2005) . , 2014; Zhang et al., 2010) . In light of these studies, elevated HSP expression is thought to be beneficial in preventing or in halting neurodegenerative disease progression (Benatar et al., 2018) . For example, overexpression of DNAJB6b and DNAJB8 suppressed toxic protein aggregation (Hageman et al., 2010) ; while overexpression of HSP70 in neuroglioma cells decreased the formation of alpha-synuclein fibrils (Outeiro et al., 2008) . Within ALS models, overexpression of HSPB8 promoted clearance of mutant SOD1 (Crippa et al., 2010) ; double transgenic mice overexpressing HSP27 and mutated SOD1 exhibited increased survival of spinal motor neurons than mice overexpressing a SOD1 mutation only, however, the neuroprotective effects were not sustained in later stages of the disease (Sharp et al., 2008) . Finally, DNAJB2, which when mutated can cause autosomal recessive spinal muscular atrophy, was overexpressed in mice motor neurons also expressing a SOD1 mutation (p.Gly93Ala), and led to reduced mutant SOD1 aggregation and improved motor neuron survival (Novoselov et al., 2013) .
While no novel genes that pass exome-wide significance have been unveiled herein, the significant exome-wide enrichment of PTVs, which seem to primarily reside in constrained genes, substantiates the polygenicicity of ALS van Rheenen et al., 2016) . Therefore, the integration of a larger number of ALS samples can potentially identify novel genes that are highly constrained, like DNAJC7, that may confer risk to ALS.
EXPERIMENTAL PROCEDURES
Study overview
The familial ALS (FALS) and the ALS Genetics (ALSGENS) consortia were assembled to aggregate the existing ALS sequencing data in the community to improve the power to discover novel genetic risk factors for ALS. Herein, we describe our approach of assembling the largest ALS exome case-control study to date.
Sample acquisition
Blood samples were collected from subjects following appropriate and informed consent in accordance with the Research Ethics Board at each respective recruiting site within the CReATe, FALS, and ALSGENS consortia. All samples known to be carriers of the C9orf72 hexanucleotide expansion (G4C2) were excluded from the study. Additionally, prior to exome sequencing, a subset of the samples (approximately 2,000) were genotyped and screened for known variants in known ALS genes, SOD1, FUS, and TARDBP; and were only included in our study if they were found to be negative for the variants tested.
Exome sequencing data for control samples were downloaded from dbGAP and were not enriched for (but not specifically screened for) ALS or other neurodegenerative disorders.
Control samples were matched to case samples with respect to similar capture kits and coverage levels. The age of control samples was not provided for all samples but in general, controls were older than typical age of onset of ALS. All samples were joint called together and were aligned to the consensus human genome sequence build GRCh37/hg19; and BAM files were processed using BWA Picard. Genotype calling was performed using the Genome Analysis Toolkit's (GATK) HaplotypeCaller and was performed at the Broad Institute as previously described (Ganna et al., 2017, BioRxiv, doi: https://doi.org/10.1101/148247).
Hail software and quality control
We used Hail, an open-source, scalable framework for exploring and analyzing genomic data https://hail.is/ to process the data. All quality control steps were performed using Hail 0.1 (Table   S1 ).
(1) Sample QC and Variant QC Samples with high proportion of chimeric reads (>5%) and high contamination (>5%) were excluded. Samples with poor call rates (<90%), mean depth <10x, or mean genotype-quality <65
were also eliminated from further analysis.
For variant QC, we restricted to GENCODE coding regions, independent of capture interval, where both Agilent and Illumina exomes surpass 10x mean coverage. We restricted to 'PASS' variants in GATK's Variant Quality Score Recalibration (VQSR) filter. Individual genotypes were filtered (set to missing) if they did not meet the following criteria: 1) genotype depth (g.DP) 10 or greater 2) Allele balance >=0.2 in heterozygous sites or <= 0.8 for homozygous reference and homozygous alternate variants 3) Genotype quality (GQ)> 20 .
Finally, we selected variants with call rate >90% and Hardy-Weinberg equilibrium test P-value >1x10 -6. For quality control analysis, see Table S1 and Figures S1.
(2) Sex imputation
We used the X chromosome inbreeding coefficient to impute sample sex. Samples with an X chromosome inbreeding coefficient >0.8 were classified as males and samples with an X chromosome inbreeding coefficient <0.4 were classified as females. Samples within <0.8 and >0.4 were classified as having ambiguous sex status, and therefore were excluded from the dataset ( Figure S2 , Table S1 ).
(3) Principal component analysis
Principal component analysis (PCA) was performed using Hail. We used a subset of high confidence SNPs in the exome capture region to calculate the principal components ( Figure   S3A ). We used only ancestry-matched cases and controls as indicated by overlapping population structure ( Figure S3B-3D) . Furthermore, we used 1000 Genomes samples to determine the general ethnicity of the ALS dataset. The majority of the samples in the ALS dataset were reported to be of European descent and this was confirmed by PCA with 1000 Genomes samples ( Figure S4 , Table S1 ).
(4) Relatedness check
We included only unrelated individuals (IBD proportion < 0.2) ( Figure S5 , Table S1 ).
(5) Variant annotation
We annotated protein-coding variants into four classes: (1) synonymous; (2) benign missense;
(3) damaging missense; and (4) protein-truncating variants (PTV). Using VEP annotations (Version 85) (McLaren et al., 2016) , we classified synonymous variants as:
"synonymous_variant", "stop_retained_variant", and "incomplete_terminal_codon_variant".
Missense variants were classified as: "inframe_deletion", "inframe_insertion", "missense_variant", "stop_lost", "start_lost", and "protein_altering_variant". Furthermore, benign missense variants were predicted as "tolerated" and "benign" by PolyPhen-2 and SIFT, respectively; whereas damaging missense variants were predicted as "probably damaging" and "deleterious". Finally, PTVs were classified as: "frameshift_variant", "splice_acceptor_variant", "splice_donor_variant", and "stop_gained".
(6) Allele frequency categorization Allele frequencies were estimated within our case-control sample, and from two external exome sequence databases, DiscovEHR and ExAC (Lek et al., 2016) . DiscovEHR is a publicly available database with >50,000 exomes of ostensibly healthy participants. ExAC is a mixture of healthy controls and complex disease patients, and we restricted to the non-psychiatric subset of ExAC for allele frequency estimation. Of note, many of our controls are present in the ExAC database, so we restricted to the DiscovEHR cohort to determine ultra-rare singletons. We did not use gnomAD for this analysis as our cases and our controls have been deposited into this resource.
We classified variant allele frequency using the following criteria: (1) singletons, which are variants present in a single individual in our dataset (allele count, AC =1); (2) doubletons, which are present in two individuals in our dataset (AC = 2); (3) ultra-rare singletons, which are singletons in our dataset and are absent in DiscovEHR (AC = 1, 0 in DiscovEHR); and finally, (4) rare variants, which have a MAF of <0.01% in our dataset (11,703 samples), in ExAC (nonpsychiatric studies, >45,000 samples) and in DiscovEHR (>50,000 samples).
Multivariate models used for analysis
To determine whether an enrichment of a specific class of variation was present in ALS cases versus controls, we ran multiple Firth logistic regression models. The Firth penalization is used in the likelihood model due to the low counts in many tests, and helps to minimize the type I error rate when multiple covariates are included in the model (Wang, 2014) . Model 1 predicted ALS case-control status solely from variant count ( Figure S6) ; Model 2 incorporated multiple covariates: (1) sample sex, (2) sample population structure from the first 10 principal components ( Figure S7) ; Model 3 incorporated all covariates used the second model along with (3) sample total exome count, which is the exome-wide count of variants in the specific frequency class tested. Finally, Model 4 is similar to Model 3, but instead uses the "benign variant" count as a covariate, which is the exome-wide count of synonymous variants and benign missense variants only, rather than total exome count ( Figure S8 ). Model 3, which we considered to be the most conservative model to represent the dataset, was used as the preferred model for our analysis ( Figure S9 ). 1
Exome-wide burden
The four Firth logistic regression models above were used to predict case-control status from exome-wide counts of synonymous, missense, and PTV variants. Given that sequencing errors are more prevalent when calling insertions or deletions (indels), we divided variants within the PTV category as either 1) SNV-based PTVs or 2) indel-based PTVs, due to single nucleotide variants (SNVs) or indels, respectively. This ensures that any enrichment observed in PTVs is not solely from indel-based PTVs.
Gene sets
(1) Constrained genes (pLI genes: 3,488, constrained missense genes: 1,730)
We evaluated whether variation in loss of function intolerant (pLI) genes are associated with ALS using the same approach as described in the exome-wide approach however, we extracted only high pLI genes from the exome. We obtained the genic pLI intolerance metrics from Lek et al., 2016 available online: (ftp://ftp.broadinstitute.org/pub/ExAC_release/release0.3/functional_gene_constraint/). For PTVs, we used genes with a probability of loss-of-function intolerant (pLI) >0.9. We also evaluated missense constrained genes generated by Samocha et al., 2014 . For missense variants, we used genes with a z-score of >3.09.
(2) ALS associated genes (38 genes)
We also examined exome-wide burden with known ALS genes removed. The list of ALS genes are as follows : TARDBP, DCTN1, ALS2, CHMP2B, ARHGEF28, MATR3, SQSTM1, FIG4, HNRNPA2B1, C9orf72, SIGMAR1, VCP, SETX, OPTN, PRPH, HNRNPA1, DAO, ATXN2, ANG, FUS, PFN1, CENPV, TAF15, GRN, MAPT, PNPLA6, UNC13A, VAPB, SOD1, NEFH, ARPP21,  and UBQLN2. We did not remove TBK1, NEK1, KIF5A, C21orf2, MOBP, or SCFD1 as these genes were discovered using datasets that contained a large subset of the same samples. We also performed an exome-wide burden analysis with all proposed ALS genes removed.
(3) Neurodegenerative disease genes (120 genes)
We investigated whether genes associated with other neurodegenerative phenotypes showed enrichment in ALS cases. We included the following motor neuron diseases: primary lateral sclerosis, progressive muscular atrophy, progressive bulbar palsy, and spinal muscular atrophy.
We also used genes associated with Parkinson's disease, frontotemporal dementia, Pick's disease, and Alzheimer's disease as patients with ALS can also present with frontotemporal dementia, cognitive impairment, or Parkinsonism (Table S2 ).
(4) Brain expressed genes (2,650 genes)
We evaluated whether genes expressed specifically in the brain were enriched for variation in our dataset. For this analysis, we used brain specific genes generated by Ganna et al., 2016 .
Single gene burden analysis
(1) ALS dataset (3,864 cases and 7,839 controls)
To determine whether a single gene is enriched or depleted for rare protein-coding variation in ALS cases, we performed a burden analysis using Fisher's exact test as well as SKAT, with previously defined covariates (sample sex, PC1-PC10, and total exome count). Exome-wide correction for multiple testing was set at (P<2.5x10 -6), which was the 5% type-I error rate multiplied by the number of genes tested. We performed four different tests in ALS cases and controls: (1) ultra-rare PTVs (AC=1 and absent in DiscovEHR); (2) ultra-rare damaging missense variants (AC=1 and absent in DiscovEHR); (3) rare PTVs (MAF <0.001% in the dataset, DiscovEHR, and ExAC); and (4) rare damaging missense variants (MAF <0.001% in the dataset, DiscovEHR, and ExAC).
(2) ALS dataset and additional controls (3,864 cases and 28,910 controls)
We also included an additional 21,071 samples from ExAC that are of European descent (nonFinnish) and were not a part of any psychiatric or brain related studies, to eliminate any sample overlap. Furthermore, to mitigate against false discoveries, in addition to passing our QC filters, we ensured each variant also passed gnomAD (123,136 exomes and 15,496 genomes) QC filters.
We included variants that were either a singleton (AC=1) in gnomAD or completely absent to ensure we minimize the inclusion of an excess of variants that passed gnomAD QC, that were rare (MAF <0.001%), yet were still observed in a very high number of individuals and were likely, false positive variants. The additional 21,071 samples allowed us to perform in part, a replication (secondary) analysis of the genes that approached statistical significance (P<2.5x10 -6) and determine whether their OR and P-values are maintained and exceed statistical significance, respectively. Additionally, we also used the 21,071 controls to increase statistical power to detect any gene discoveries not detected in the original dataset. Importantly, we did not perform a joint PCA on the 21,071 non-Finnish European controls and our dataset, therefore, we are unable to completely match the ancestry of our dataset. 
TABLES
FIGURES Figure 1. Exome wide enrichment of PTVs in ALS cases
Exome wide analysis of synonymous variants, benign missense variants, damaging missense variants, and PTVs within singletons (AC=1), doubletons (AC=2), ultra-rare singletons (AC=1, 0 in DiscovEHR), and rare variants (MAF<0.01 in our dataset, DiscovEHR and ExAC). Odds ratios and 95% confidence intervals for each class of variation are depicted by different colors.
P-values are also displayed. Multiple test correction P-value: 0.0125. 
